跳至主要内容
临床试验/NCT00320229
NCT00320229终止4 期

Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen

Azienda Sanitaria Ospedaliera2 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2004年12月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
终止
发起方
入组人数
84
试验地点
2

研究概览

简要总结

The aim of our study was to demonstrate that, during a percutaneous coronary intervention, even smaller amounts of abciximab than standard dose, injected locally, could achieve a rapid thrombus resolution and clinical improvement without concomitant differences in hemorrhagic complications

详细描述

Patients both with acute myocardial infarction and unstable angina are prone to extensive intracoronary thrombosis, leading to acute deterioration during percutaneous coronary intervention or thrombosis of the device despite therapy. Intracoronary use of abciximab has reported favourable results. We randomly assigned 84 patients to intracoronary half abciximab bolus (group A) and to standard regimen (group B).

研究设计

研究类型
Interventional

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • presenting with unstable angina
  • presenting with acute myocardial infarction
  • eligibility for percutaneous coronary intervention

排除标准

  • presenting with cardiogenic shock

研究者

发起方
Azienda Sanitaria Ospedaliera
申办方类型
Other

研究点 (2)

Loading locations...

相似试验